title: [Effect of recombinant heat-shock protein (rHSP70) of Mycobacterium tuberculosis on immunogenicity of Haemophilus influenzae type B capsular polysaccharide].
abstract: OBJECTIVE
  To study effect of recombinant heat-shock protein (rHSP70) of Mycobacterium tuberculosis on immunogenicity of Haemophilus influenzae type b capsular polysaccharide (CPSHib).
  
  
  METHODS
  Capsular polysaccharide was obtained by precipitation with cetavlon, antibody titers and Toll-like receptors (TLRs) were detected by enzyme immunoassay and flow cytometry respectively.
  
  
  RESULTS
  rHSP70 modified immune response to chemically conjugated and unconjugated CPSHib. rHSP70 enhanced expression of TLRs 2, 4, 9 on mice splenocytes; increased levels of CD3+, CD8+, NK, CD3/NK (NKT) lymphocytes. Levels of CD4+, CD25+ (markers of early activation of T-helpers) as well as MHC class II molecules were increased that could be appraised as a shift from T-independent to T-dependent immune response. Difference in antibody titers after 2- or 3-dose immunization of mice with 5 mcg/dose of CPSHib in mixture or conjugated with rHSP70 was not revealed. Level of antibodies to rHSP70 in serum samples of mice immunized with CPSHib conjugated with rHSP70 was 6.55 - 8.4 times higher compared to unimmunized animals. Antibodies, which have common antigenic epitopes to human organs and tissues, were not detected.
  
  
  CONCLUSIONS
  rHSP70 modifies immune response to CPSHib.
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Shevchik
authors.forename: O V
authors.initials: OV
authors.lastname: Novikova
authors.forename: N K
authors.initials: NK
authors.lastname: Akhmatova
authors.forename: E A
authors.initials: EA
authors.lastname: Kurbatova
authors.forename: P G
authors.initials: PG
authors.lastname: Sveshnikov
authors.forename: N E
authors.initials: NE
authors.lastname: Iastrebova
authors.forename: N P
authors.initials: NP
authors.lastname: Vaneeva
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D015703:Antigens, CD / Q000096:biosynthesis; D016667:Bacterial Capsules / Q000008:administration & dosage / Q000276:immunology*; D001426:Bacterial Proteins / Q000008:administration & dosage / Q000276:immunology*; D018840:HSP70 Heat-Shock Proteins / Q000008:administration & dosage / Q000276:immunology*; D018073:Haemophilus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007114:Immunization; D007274:Injections, Intraperitoneal; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D013154:Spleen / Q000276:immunology / Q000378:metabolism; D051193:Toll-Like Receptors / Q000096:biosynthesis
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D015703:Antigens, CD; D001426:Bacterial Proteins; D018840:HSP70 Heat-Shock Proteins; C444642:HSP70 protein, Mycobacterium tuberculosis; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D011994:Recombinant Proteins; D051193:Toll-Like Receptors